Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors

被引：54

作者：

Zhang, Zhimin ^{[1
]}

Hou, Shaohua ^{[1
]}

Chen, Hongli ^{[1
]}

Ran, Ting ^{[2
]}

Jiang, Fei ^{[1
]}

Bian, Yuanyuan ^{[1
]}

Zhang, Dewei ^{[1
]}

Zhi, Yanle ^{[1
]}

Wang, Lu ^{[1
]}

Zhang, Li ^{[1
]}

Li, Hongmei ^{[1
]}

Zhang, Yanmin ^{[2
]}

Tang, Weifang ^{[1
]}

Lu, Tao ^{[2
,3
]}

Chen, Yadong ^{[2
]}

机构：

[1] Sch Sci, Dept Organ Chem, 639 Longmian Ave, Nanjing 211198, Jiangsu, Peoples R China

[2] Sch Sci, Lab Mol Design & Drug Discovery, 639 Longmian Ave, Nanjing 211198, Jiangsu, Peoples R China

[3] China Pharmaceut Univ, State Key Lab Nat Med, 24 Tongjiaxiang, Nanjing 210009, Jiangsu, Peoples R China

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2016年 / 26卷 / 12期

基金：

中国国家自然科学基金;

关键词：

Epigenetic; Protein-protein interactions; Bromodomain; HDAC; Antiproliferative activity; BROMODOMAIN; DISCOVERY;

D O I：

10.1016/j.bmcl.2016.04.034

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The bromodomain protein module and histone deacetylase ( HDAC), which recognize and remove acetylated lysine, respectively, have emerged as important epigenetic therapeutic targets in cancer treatments. Herein we presented a novel design approach for cancer drug development by combination of bromodomain and HDAC inhibitory activity in one molecule. The designed compounds were synthesized which showed inhibitory activity against bromodomain 4 and HDAC1. The representative dual bromodomain/HDAC inhibitors, compound 11 and 12, showed potent antiproliferative activities against human leukaemia cell line K562 and MV4-11 in cellular assays. This work may lay the foundation for developing dual bromodomain/HDAC inhibitors as potential anticancer therapeutics. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：2931 / 2935

页数：5

共 50 条

[31] Design, synthesis and biological evaluation of novel 4,5-dihydro-[1,2,4] triazolo[4,3-f] pteridine derivatives as potential BRD4 inhibitors
Bi, Xinzhou
Li, Jieming
Li, Jiuhui
Shi, Wei
Dai, Yuxuan
Li, Qifei
Zhang, Wenjie
Huang, Wenlong
Qian, Hai
Jiang, Cheng
BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (13) : 2813 - 2821
[32] Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation
Liu, Zhiqing
Chen, Haiying
Wang, Pingyuan
Li, Yi
Wold, Eric A.
Leonard, Paul G.
Joseph, Sarah
Brasier, Allan R.
Tian, Bing
Zhou, Jia
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (10) : 5242 - 5256
[33] Synthesis, evaluation and in silico studies of novel BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold
Zhang, Maofeng
Liu, Zhuyun
Wang, Lizhong
Li, Yan
Ma, Yonggang
JOURNAL OF CHEMICAL SCIENCES, 2021, 133 (01)
[34] Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury
Vittoria Borgonetti
Elisabetta Meacci
Federica Pierucci
Maria Novella Romanelli
Nicoletta Galeotti
Neurotherapeutics, 2022, 19 : 1634 - 1648
[35] Synthesis, evaluation and in silico studies of novel BRD4 bromodomain inhibitors bearing a benzo[d]isoxazol scaffold
Maofeng Zhang
Zhuyun Liu
Lizhong Wang
Yan Li
Yonggang Ma
Journal of Chemical Sciences, 2021, 133
[36] Design, synthesis, and biological evaluation of quinazoline derivatives as dual HDAC1 and HDAC6 inhibitors for the treatment of cancer
Chen, Jinying
Sang, Zitai
Jiang, Youjun
Yang, Chao
He, Linhong
CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 93 (03) : 232 - 241
[37] Synthesis and biological evaluation of novel 4-Arylaminoquinolines derivatives as EGFR/HDAC inhibitors
Yao, Keke
Li, Yaxin
Wei, Wei
Liu, Sisi
Wang, Xiaoli
Xu, Jiamin
Zhang, Ranran
Wu, Zhigang
Guo, Chunyan
Yang, Leifu
Hu, Liming
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2025, 122
[38] Design, synthesis and biological evaluation of novel pyrazinone derivatives as PI3K/HDAC dual inhibitors
Wang, Zi-Xiao
Wang, Shuai
Qiao, Xue-Peng
Li, Wen-Bo
Shi, Jian-Tao
Wang, Yi-Ru
Chen, Shi-Wu
BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 74
[39] Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors
Dong, Hang
Yin, Hao
Zhao, Chunlong
Cao, Jiangying
Xu, Wenfang
Zhang, Yingjie
MOLECULES, 2019, 24 (13):
[40] Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC
Peng, Fan-Wei
Xuan, Ji
Wu, Ting-Ting
Xue, Jia-Yu
Ren, Zi-Wei
Liu, Da-Ke
Wang, Xiu-Qi
Chen, Xin-Hang
Zhang, Jia-Wei
Xu, Yun-Gen
Shi, Lei
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2016, 109 : 1 - 12

← 1 2 3 4 5 →